Valneva raises US$85m
French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2152 entries already.
Entries by Thomas Gabrielczyk
EMA greenlights 15 new meds
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
European Biotechnology Guide 2020
The 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Sleeping sickness target deciphered
Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
UK researchers present dengue virus transmission map
Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
AMR: IMI’s Enable project reaches endpoints
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
MercachemSyncom, Bionetix, and ProQinase ink AML contract
Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
iOnctura SA bags €15m in Series A round
Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
Nestlé heavily invests in sustainable packaging
Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives.
BioNTech acquires Neon at cheapest for $67m
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.